Whither HER2-related therapeutics?

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1091-1096

  De, Pradip ^a   Leyland Jones, Brian ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER INHIBITION; CANCER SURVIVAL; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EDITORIAL; FEMALE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC ACQUIRED RESISTANCE; DRUG ANTAGONISM; NEOPLASM; PHYSIOLOGY;

HUMANS; NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 77949899466     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.8624     Document Type: Editorial

References (52)

1. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N Engl J Med 353:1734-1736, 2005
2. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002 (Pubitemid 34111379)
3. Osipo C, Patel P, Rizzo P, et al: ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27: 5019-5032, 2008
4. Agus DB, Gordon MS, Taylor C, et al: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543, 2005 (Pubitemid 47050843)
5. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002 (Pubitemid 41039113)
6. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004 (Pubitemid 38482068)
7. Werner Scheuer TF, Burtscher H, Bossenmaier B, et al: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330-9336, 2009
8. DiGiovanna MP, Stern DF, Edgerton SM, et al: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23:1152-1160, 2005 (Pubitemid 46202271)
9. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68:5878-5887, 2008
10. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
11. Nahta R, Yuan LX, Du Y, et al: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 6:667-674, 2007 (Pubitemid 46332467)
12. Gril B, Palmieri D, Bronder JL, et al: Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-1103, 2008
13. Leyland-Jones B: Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278-5286, 2009
14. Gelman K, Fumoleau P, Verma S, et al: Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 26:47s, 2008 (suppl; abstr 1026)
15. Zhang X, Gureasko J, Shen K, et al: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149, 2006 (Pubitemid 43866200)
16. Holbro T, Beerli RR, Maurer F, et al: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938, 2003 (Pubitemid 36899201)
17. Berger MB, Mendrola JM, Lemmon MA: ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 569:332-336, 2004 (Pubitemid 38849407)
18. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102:802-807, 2005 (Pubitemid 40282746)
19. Gordon MS, Matei D, Aghajanian C, et al: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324-4332, 2006 (Pubitemid 46630791)
20. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144, 2010
21. Blackwell KL, Pegram MD, Tan-Chiu E, et al: Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20:1026-1031, 2009
22. Pegram MCD, Dichmann R, et al: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as a first line treatment of HER2- amplified breast cancer, Proceedings of the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2006 (abstr 301)
23. Gianni L, Lladó A, Bianchi G, et al: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:1131-1137, 2010
24. Yao E, Zhou W, Lee-Hoeflich ST, et al: Suppression of HER2/HER3- mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 15:4147-4156, 2009
25. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
26. Hynes NE, Dey JH: PI3K inhibition overcomes trastuzumab resistance: Blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 15:353-355, 2009
27. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091, 2008
28. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004 (Pubitemid 39485684)
29. Faratian D, Goltsov A, Lebedeva G, et al: Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 69:6713-6720, 2009
30. She QB, Chandarlapaty S, Ye Q, et al: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3:e3065, 2008
31. Muller JM: Role of PI3K and AKT coupled signaling pathways in mammary development and tumorigenesis. Advances in Breast Cancer Research Meeting, San Diego, CA, October 13-16, 2009
32. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022-8030, 2008
33. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
34. Li YM, Zhou BP, Deng J, et al: A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 65:3257-3263, 2005 (Pubitemid 40524609)
35. Garlich JR, De P, Dey N, et al: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68:206-215, 2008 (Pubitemid 351380122)
36. Giatromanolaki A, Koukourakis MI, Simopoulos C, et al: C-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 10:7972-7977, 2004 (Pubitemid 39587538)
37. Rugo HS: Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 9:43-49, 2004 (suppl 1)
38. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
39. Kavanagh DO, Chambers G, O'Grady L, et al: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9:1, 2009
40. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290, 2008
41. Modi MBS, Krop IE, Rabbee N, et al: A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2-antibody drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). Presented at American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, CA, September 7-8, 2007
42. Bostrom J, Yu SF, Kan D, et al: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610-1614, 2009
43. Bai T, Luoh SW: GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis 29:473-479, 2008 (Pubitemid 351404862)
44. Nadler Y, Gonzalez AM, Camp RL, et al: Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol [epub ahead of print on August 28, 2009]
45. Pero SC, Shukla GS, Cookson MM, et al: Combination treatment with Grb7 peptide and doxorubicin or trastuzumab (herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br J Cancer 96:1520-1525, 2007 (Pubitemid 46762945)
46. Heasman SJ, Ridley AJ: Mammalian rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 9:690-701, 2008
47. Ueda Y, Wang S, Dumont N, et al: Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279:24505-24513, 2004 (Pubitemid 38725316)
48. Schnelzer A, Prechtel D, Knaus U, et al: Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19:3013-3020, 2000 (Pubitemid 30389092)
49. Fritz G, Kaina B: Rho GTPases: Promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 6:1-14, 2006
50. Dokmanovic M, Hirsch DS, Shen Y, et al: Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 8:1557-1569, 2009
51. Moelans CB, de Weger RA, van Blokland MT, et al: Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol 23:62-70, 2010
52. Makhija S, Amler LC, Glenn D, et al: Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215-1223, 2010